Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2024
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Samuraciclib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Carrick Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Samuraciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Carrick Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosnetupitant Chloride,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 27, 2020
Lead Product(s) : Fosnetupitant Chloride,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nebivolol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2010
Lead Product(s) : Nebivolol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable